Hormone replacement therapy for secondary prevention of coronary heart disease.

[1]  V. Beral,et al.  Hormone Replacement Therapy: Patient Education Crucial , 1999, The Lancet.

[2]  D. Petitti.  Hormone replacement therapy and heart disease prevention: experimentation trumps observation. , 1998, JAMA.

[3]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[4]  S B Hulley,et al.  Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. , 1998, Controlled clinical trials.

[5]  R Smith,et al.  Beyond conflict of interest. Transparency is the key. , 1998, BMJ.

[6]  M. Pfeffer,et al.  Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. , 1998, Journal of the American College of Cardiology.

[7]  S. Sidney,et al.  Myocardial Infarction and the Use of Estrogen and Estrogen-Progestogen in Postmenopausal Women , 1997, Annals of Internal Medicine.

[8]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[9]  B. Psaty,et al.  Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. , 1997, Archives of internal medicine.

[10]  H. Parving,et al.  Population based study of rates of multiple pregnancies in denmark, 1980-94 , 1997, BMJ.

[11]  J. Rösch,et al.  Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm , 1997, Nature Medicine.

[12]  J. Vandenbroucke,et al.  Risk of venous thrombosis with hormone-replacement therapy , 1996, The Lancet.

[13]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[14]  V. Jp.  How much of the cardioprotective effect of postmenopausal estrogens is real , 1995 .

[15]  J. Sullivan.  IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK , 1981, The Lancet.

[16]  S. Sidney,et al.  Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy. , 1998, Stroke.